Net debt/EBITDA společnosti Theratechnologies
Jaká je hodnota metriky Net debt/EBITDA společnosti Theratechnologies?
Hodnota metriky Net debt/EBITDA společnosti Theratechnologies, Inc. je -4.31
Jaká je definice metriky Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA společností v sektoru Health Care sektor na TSX ve srovnání se společností Theratechnologies
Čemu se věnuje společnost Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Firmy s metrikou net debt/ebitda podobnou společnosti Theratechnologies
- Hodnota metriky Net debt/EBITDA společnosti Castor Maritime je -4.32
- Hodnota metriky Net debt/EBITDA společnosti BigCommerce je -4.32
- Hodnota metriky Net debt/EBITDA společnosti EVS Broadcast Equipment S.A je -4.32
- Hodnota metriky Net debt/EBITDA společnosti Global Indemnity je -4.31
- Hodnota metriky Net debt/EBITDA společnosti Align Technology je -4.31
- Hodnota metriky Net debt/EBITDA společnosti TG Therapeutics Inc je -4.31
- Hodnota metriky Net debt/EBITDA společnosti Theratechnologies je -4.31
- Hodnota metriky Net debt/EBITDA společnosti Natus Medical Inc je -4.31
- Hodnota metriky Net debt/EBITDA společnosti Telefonaktiebolaget LM Ericsson (publ) je -4.30
- Hodnota metriky Net debt/EBITDA společnosti Morris je -4.30
- Hodnota metriky Net debt/EBITDA společnosti Ortho Regenerative Technologies je -4.30
- Hodnota metriky Net debt/EBITDA společnosti Marine Products Corp je -4.30
- Hodnota metriky Net debt/EBITDA společnosti Ramsdens PLC je -4.30